Highly selective H3 receptor antagonist (Ki values are 0.30, 365 and 3621 μM for H3, H2 and H1 receptors respectively). Acts as a natural antioxidant with hydroxyl radical scavenging and lipid peroxidase activities.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 410.27. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.44 mL||12.19 mL||24.37 mL|
|5 mM||0.49 mL||2.44 mL||4.87 mL|
|10 mM||0.24 mL||1.22 mL||2.44 mL|
|50 mM||0.05 mL||0.24 mL||0.49 mL|
References are publications that support the products' biological activity.
Babizhayev et al (1994) L-Carnosine (β-alanyl-L-histidine) and carcinine (β-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem.J. 304 509 PMID: 7998987
Chen et al (2004) Pharmacological effects of carcinine on histaminergic neurons in the brain. Br.J.Pharmacol. 143 573 PMID: 15466447
If you know of a relevant reference for Carcinine ditrifluoroacetate, please let us know.
View Related Products by Product Action
Keywords: Carcinine ditrifluoroacetate, supplier, Highly, selective, H3, antagonists, Histamine, Receptors, histaminergic, Histamine, H3, Receptors, Histamine, H3, Receptors, Tocris Bioscience
Citations for Carcinine ditrifluoroacetate
Citations are publications that use Tocris products.
Currently there are no citations for Carcinine ditrifluoroacetate. Do you know of a great paper that uses Carcinine ditrifluoroacetate from Tocris? If so please let us know.
Carcinine ditrifluoroacetate Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.